Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/hdi.12997 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Diseases Separated from Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Anti-Myelin-Associated Glycoprotein Neuropathy and Autoimmune Nodopathy].
Brain Nerve
January 2025
Internal Medicine, Morioka Health Cooperative Association, Kawakubo Hospital.
Anti-myelin-associated glycoprotein (Anti-MAG) neuropathy and autoimmune nodopathies with antibodies targeting nodal or paranodal proteins have recently been reclassified as distinct conditions, separate from chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). This distinction is based on the clinical homogeneity observed in antibody-positive cases, their unique response to treatment compared to CIDP, and evidence indicating the pathogenic role of these autoantibodies. The significance of identifying conditions outside the CIDP category lies in the elucidation of their distinct pathological mechanisms and providing appropriate immunotherapy accordingly.
View Article and Find Full Text PDFKlotho supplementation decreases blood pressure and albuminuria in mice with lupus nephritis.
Eur J Pharmacol
December 2024
Keio University, Tokyo, Japan.
Klotho deficiency is prevalent in various chronic kidney diseases. Although klotho is known to bind transforming growth factor β (TGFβ) receptor 1 to antagonize renal fibrosis, TGFβ also maintains regulatory T cells with inducing forkhead box protein P3 (FOXP3). Female New Zealand Black/White F (NZBWF1) mice were divided into two groups (n=10 for each): one group was treated with daily subcutaneous injection of klotho protein (30 μg/kg/day) for 8 weeks, and the other only received vehicle.
View Article and Find Full Text PDFSARS-CoV-2 SPIKE Antibody Levels can Indicate Immuno-Resilience to Re-infection: a Real-World Study.
Infect Dis Ther
December 2024
Roche Diagnostics GmbH, Nonnenwald 2, 81377, Penzberg, Germany.
Introduction: The use of antibody titers against SARS-CoV-2, as a method of estimating subsequent infection following infection or vaccination, is unclear. Here, we investigate whether specific levels of antibodies, as markers of adaptive immunity, can serve to estimate the risk of symptomatic SARS-CoV-2 (re-) infection.
Methods: In this real-world study, laboratory data from individuals tested for SARS-CoV-2 antibodies under routine clinical conditions were linked through tokenization to a United States medical insurance claims database to determine the risk of symptomatic/severe SARS-CoV-2 infection outcomes.
Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy.
JAMA Oncol
December 2024
Institute of Experimental Oncology, University Hospital Bonn, Bonn, Germany.
Importance: Progressive disease (PD) in patients treated with immune checkpoint inhibitors (ICIs) varies widely in outcomes according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Efforts to modify RECIST for ICI treatment have not resolved the heterogeneity in PD patterns, posing a clinical challenge.
View Article and Find Full Text PDFDose-dependent serological profiling of AdCLD-CoV19-1 vaccine in adults.
mSphere
December 2024
International Vaccine Institute, Seoul, South Korea.
AdCLD-CoV19-1, a chimeric adenovirus-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, was previously reported to elicit robust antibody responses in mice and non-human primates after a single dose. In this study, we conducted a systems serology analysis to investigate changes in humoral immune responses induced by varying doses of the AdCLD-CoV19-1 vaccine in a phase I clinical trial. Serum samples from participants receiving either a low or a high dose of the vaccine were analyzed for antibody features against prototype SARS-CoV-2 spike (S) domains (full-length S, S1, S2, and receptor binding domain), as well as Fc receptor binding and effector functions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!